130 related articles for article (PubMed ID: 37734837)
21. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model.
Xie W; Liu MK; Jiang XF; Gao XD; Li B; Wang L; Zhao WL
Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799
[TBL] [Abstract][Full Text] [Related]
22. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
23. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
24. Can the SUV
Zhang Y; Fan Y; Ying Z; Song Y; Zhu J; Yang Z; Wang X
Leuk Lymphoma; 2018 Mar; 59(3):660-669. PubMed ID: 28771052
[TBL] [Abstract][Full Text] [Related]
25. [The prognosis value of early and interim ¹⁸F-FDG-PET/CT scans in patients with diffuse large B-cell lymphoma].
Zhang Y; Fan Y; Yang Z; Ying Z; Song Y; Zhu J; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2015 Oct; 36(10):824-9. PubMed ID: 26477759
[TBL] [Abstract][Full Text] [Related]
26. Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the ΔSUVmax method.
Ng DZ; Lee CY; Lam WW; Tong AK; Tan SH; Khoo LP; Tan YH; Chiang J; Chang EW; Chan JY; Poon EY; Somasundaram N; Farid H Rashid M; Tao M; Lim ST; Yang VS
Leuk Lymphoma; 2022 Jan; 63(1):256-259. PubMed ID: 34665693
[TBL] [Abstract][Full Text] [Related]
27. Prognostic parameters on baseline and interim [ 18 F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients.
Czibor S; Carr R; Redondo F; Auewarakul CU; Cerci JJ; Paez D; Fanti S; Györke T
Nucl Med Commun; 2023 Apr; 44(4):291-301. PubMed ID: 36705233
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.
Lombion N; Robin P; Tempescul A; LE Roux PY; Schick U; Guillerm G; Ianotto JC; Berthou C; Salaün PY; Abgral R
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):402-409. PubMed ID: 35133099
[TBL] [Abstract][Full Text] [Related]
29. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
30. Risk Assessment in Diffuse Large B-Cell Lymphoma by Combining Baseline Metabolic Tumor Volume and Peking Criteria When Evaluating Series
Yuan T; Zhang Y; Chen X; Wei M; Zhu H; Song Y; Yang Z; Zhu J; Wang X
Front Oncol; 2022; 12():876581. PubMed ID: 35530320
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL
Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264
[TBL] [Abstract][Full Text] [Related]
32. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
[TBL] [Abstract][Full Text] [Related]
35. End-of-treatment
Allioux F; Gandhi D; Vilque JP; Nganoa C; Gac AC; Aide N; Lasnon C
Leuk Lymphoma; 2021 Dec; 62(12):2890-2898. PubMed ID: 34219589
[TBL] [Abstract][Full Text] [Related]
36. [
Cohen D; Luttwak E; Beyar-Katz O; Hazut Krauthammer S; Bar-On Y; Amit O; Gold R; Perry C; Avivi I; Ram R; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):953-962. PubMed ID: 34480603
[TBL] [Abstract][Full Text] [Related]
37.
Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
[TBL] [Abstract][Full Text] [Related]
38. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation--where do we stand?
Meignan M; Itti E; Gallamini A; Haioun C
Leuk Lymphoma; 2009 Nov; 50(11):1753-6. PubMed ID: 19863178
[TBL] [Abstract][Full Text] [Related]
39. Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.
Baek DW; Cho HJ; Kim JH; Sohn SK; Song GY; Ahn SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Jeong SY; Hong CM; Min JJ; Moon JH; Yang DH
In Vivo; 2020; 34(4):2127-2134. PubMed ID: 32606193
[TBL] [Abstract][Full Text] [Related]
40. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Sibon D; Bonnet C; Berriolo-Riedinger A; Edeline V; Parrens M; Damotte D; Coso D; André M; Meignan M; Rossi C
J Clin Oncol; 2022 Apr; 40(10):1091-1101. PubMed ID: 34990281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]